Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 44

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 44
---
 service provider. |

We require materials from
suppliers that are cGMP compliant. All of our raw material suppliers are cGMP-compliant at the present. If these suppliers do not successfully
carry out their contractual duties or manufacture our raw materials in accordance with regulatory requirements, we will not be able to
submit our NDA as planned or complete, or may be delayed in completing, the clinical trials required for approval of our Gelrin platform
product candidates. In such instances, we may need to locate an appropriate replacement third-party relationship, which may not be readily
available or on acceptable terms, which would cause additional delay or increased expense prior to the approval of our Gelrin platform
product candidates and would thereby have a material adverse effect on our business, financial condition, results of operations and prospects.

Our reliance on third parties requires us to share our trade secrets and intellectual property, which increases the possibility that a competitor will discover them or that our trade secrets and intellectual property will be misappropriated or disclosed.

Because we rely on third parties
to provide us with the materials and services that we use to develop and, if appropriate in the future, manufacture our product candidates
or approved products, we may, at times, share trade secrets and intellectual property with such third parties. We seek to protect our
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, such as trade secrets and intellectual property. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized
use or disclosure would impair our competitive position and may have a material adverse effect on our business. In addition, certain of
our officers are also engaged by third parties, including our Chief Financial Officer, which provides his services to us through a third
party service firm. See “Management—Engagement Agreements with Executive Officers” for additional information.

Despite our efforts to protect
our trade secrets and knowhow, our competitors may